Dr Tamara Milder
Research Associate
Bachelor of Medicine Bachelor of Surgery Honours Class 1, UNSW Sydney (2011)
Fellow of the Royal Australasian College of Physicians (Adult Medicine Division - specialist endocrinologist) (2018)
Master of Medicine (Clinical Epidemiology), University of Sydney (2019)
Doctor of Philosophy (PhD), UNSW Sydney (2025)
Medicine & Health
School of Population Health
I am a Senior Research Associate in the Medicines Intelligence Research Program in the School of Population Health. I also work as an endocrinologist in St Vincent's Clinic and in Randwick. I have a Master of Medicine (Clinical Epidemiology) from the University of Sydney and in 2025 was awarded a PhD from UNSW Sydney. My PhD focussed on the effective and safe use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), critical medicines in the treatment of type 2 diabetes, heart failure and chronic kidney disease. My research work focuses on pharmacotherapy for cardiovascular-kidney-metabolic (CKM) syndrome including SGLT2i and glucagon-like peptide-1 receptor agonists (GLP-1 RA). It is of great importance that those with greatest need for these medicines can receive them.
E-mail
Location
Samuels Building (F25)
- Publications
- Media
- Grants
- Awards
- Research Activities
- Engagement
- Teaching and Supervision
2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Collaborative Grant, $30,000
2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Symposium Best Oral Presentation
As an endocrinologist, I have a strong clinical and academic interest and expertise in diabetes pharmacotherapy, specifically medicines with major cardiac and renal benefits - sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). I have explored the implementation of SGLT2i through a mixed-methodology approach, having both undertaken novel qualitative and pharmacoepidemiology studies. As a member of the Medicines Intelligence Research Program, I have explored the uptake of SGLT2i and GLP-1 RA in people with type 2 diabetes in New South Wales and Australia. These projects have shown a considerable underutilisation of these cardiorenal medicines, as well as geographic variation in their use. We are expanding our implementation studies about these medicines.
I also have an interest in the perioperative management of people using SGLT2i and GLP-1 RA, and have published reviews and works on this subject.